Search Press releases Keywords From To Category Therapy AreasAxial spondyloarthritisChronic inflammatory demyelinating polyneuropathyCrohn's diseaseEpilepsyHidradenitis suppurativaImmune ThrombocytopeniaImmune-mediated necrotizing myopathyLupusMyasthenia gravisOsteoporosisParkinson's diseaseProgressive supranuclear palsyPsoriasisPsoriatic arthritisRestless legs syndromeRheumatoid Arthritis TopicCorporateFinancialsPartnershipsPipeline progressResearch UCB MedicinesbimekizumabBriviactCimziaEvenityNayzilamNeuproVimpat 7 Dec 2022 The Lancet Publishes Results from Two Bimekizumab Phase 3 Studies in Psoriatic Arthritis Read More 1 Dec 2022 UCB to present data at the American Epilepsy Society 76th Annual Meeting 2022 supporting a decades-long commitment to transforming epilepsy care Read More 22 Nov 2022 UCB Submits Response to FDA Complete Response Letter for Bimekizumab Read More 14 Nov 2022 UCB announces U.S. FDA acceptance of new drug application and EMA MAA validation for zilucoplan for the treatment of generalized myasthenia gravis in adult patients Read More 10 Nov 2022 Bimekizumab Demonstrated Sustained Clinical Responses to Week 52 in Phase 3 Studies in Psoriatic Arthritis, Non-Radiographic Axial Spondyloarthritis and Ankylosing Spondylitis Read More 8 Nov 2022 UCB Reinforces Commitment to Rheumatology with 15 Abstracts including New Late-Breaking Data at ACR Convergence 2022 Read More Pagination First page Previous page Previous … Page 2 Page 3 Page 4 Page 5 Current page 6 Page 7 Page 8 Page 9 Page 10 … Next page Next Last page Stay up-to-date on the latest news and information from UCB Subscribe
